Feature | March 31, 2014

Terumo to Purchase Arterial Remodeling Technologies’ Bioresorbable Stent Technology

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corp. will make staged R&D investments in ART, and ART has granted an exclusive option to Terumo Corp. to purchase ART at any time prior to the initiation of clinical trials.

ART’s advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.

ART wishes to thank its investors: Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement & Gestion, Vesale Partners and Amundi Asset Management.

ART also wishes to thank three esteemed institutions for their invaluable support: the Cleveland Clinic; the French national research institute, CNRS, Montpellier, France; and Descartes University, Paris.

ART’s bioresborbable stent is not approved for investigational use or sale in the United States.

For more information: www.art-stent.com, www.terumomedical.com

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init